A magnesium based phosphate binder reduces vascular calcification without affecting bone in chronic renal failure rats

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Neven, Ellen ^a   De Schutter, Tineke M ^a   Dams, Geert ^a   Gundlach, Kristina ^b   Steppan, Sonja ^b   Büchel, Janine ^b   Passlick Deetjen, Jutta ^c   D'Haese, Patrick C ^a   Behets, Geert J ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b FRESENIUS MEDICAL CARE   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CALCIUM; CALCIUM ACETATE MAGNESIUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; BIOLOGICAL MARKER; CALCIUM ACETATE; CALCIUM DERIVATIVE; MAGNESIUM; MAGNESIUM CARBONATE;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE REMODELING; BONE TURNOVER; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DEPLETION; DRUG EFFECT; LOW DRUG DOSE; MALE; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOID; RAT; ANIMAL; BLOOD; BONE; DIET; DISEASE MODEL; DRUG EFFECTS; METABOLISM; URINE;

RATTUS;

ACETATES; ANIMALS; BIOMARKERS; BONE AND BONES; BONE REMODELING; CALCIUM COMPOUNDS; DIET; DISEASE MODELS, ANIMAL; KIDNEY FAILURE, CHRONIC; MAGNESIUM; MALE; PHOSPHATES; PHOSPHORUS; RATS; VASCULAR CALCIFICATION;

EID: 84907190245     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107067     Document Type: Article

References (22)

1. Barreto DV, de Carvalho BF, de Carvalho AB, Cuppari L, Draibe SA, et al. (2008) Association of Changes in Bone Remodeling and Coronary Calcification in Hemodialysis Patients: A Prospective Study. Am J Kidney Dis 52: 1139-50.
2. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, et al. (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15: 1943-1951.
3. de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, et al. (2010) Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerabil-ity. Nephrol Dial Transplant 25: 3707-3717.
4. De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, et al. (2013) Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int 83: 1109-1117.
5. Rodriguez M, Felsenfeld AJ, Llach F (1989) The evolution of osteomalacia in the rat with acute aluminum toxicity. J Bone Miner Res 4: 687-696.
6. D'Haese PC, Couttenye MM, De Broe ME (1996) Diagnosis and treatment of aluminium bone disease. Nephrol Dial Transplant 11 Suppl 3: 74-79.
7. Brancaccio D, Cozzolino M (2007) Lanthanum carbonate: time to abandon prejudices? Kidney Int 71: 190-192.
8. Persy VP, Behets GJ, Bervoets AR, De Broe ME, D'Haese PC (2006) Lanthanum: a safe phosphate binder. Semin Dial 19: 195-199.
9. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, et al. (2013) Standardized nomenclature, symbols, and units for bone histomorphom-etry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28: 2-17.
10. Andress DL, Maloney NA, Coburn JW, Endres DB, Sherrard DJ (1987) Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy. J Clin Endocrinol Metab 65: 11-16.
11. Andress DL, Maloney NA, Endres DB, Sherrard DJ (1986) Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. J Bone Miner Res 1: 391-398.
12. Couttenye MM, D'Haese PC, Deng JT, Van Hoof VO, Verpooten GA, et al. (1997) High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 12: 2144-2150.
13. Bellows CG, Heersche JN, Aubin JE (1999) Aluminum accelerates osteoblastic differentiation but is cytotoxic in long-term rat calvaria cell cultures. Calcif Tissue Int 65: 59-65.
14. Firling CE, Hill TA, Severson AR (1999) Aluminum toxicity perturbs long bone calcification in the embryonic chick. Arch Toxicol 73: 359-366.
15. Jablonski G, Klem KH, Danielsen CC, Mosekilde L, Gordeladze JO (1996) Aluminium-induced bone disease in uremic rats: effect of deferoxamine. Biosci Rep 16: 49-63.
16. Rodriguez M, Felsenfeld AJ, Llach F (1989) The evolution of osteomalacia in the rat with acute aluminum toxicity. J Bone Miner Res 4: 687-696.
17. Behets GJ, Dams G, Vercauteren SR, Damment SJ, Bouillon R, et al. (2004) Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 15: 2219-2228.
18. Bervoets AR, Oste L, Behets GJ, Dams G, Blust R, et al. (2006) Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats. Bone 38: 803-810.
19. Oste L, Behets GJ, Dams G, Bervoets AR, Marynissen RL, et al. (2007) Role of dietary phosphorus and degree of uremia in the development of renal bone disease in rats. Ren Fail 29: 1-12.
20. Behets GJ, Gritters M, Dams G, De Broe ME, D'Haese PC (2005) Effects of efficient phosphate binding on bone in chronic renal failure rats. Ren Fail 27: 475-484.
21. Covic A, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Ghenu A, et al. (2013) A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant 28: 2383-2392.
22. Vetter T, Lohse MJ (2002) Magnesium and the parathyroid. Curr Opin Nephrol Hypertens 11: 403-410.